1st Quarter - Report

ERVIN GRAVES STRATEGY GROUP, LLC for EMERGENT BIOSOLUTIONS INC.

Period 1st Quarter 2022 Filed Apr 19, 2022 Signed by John Thomas Graves Jr.

Official filing
Firm
ERVIN GRAVES STRATEGY GROUP, LLC
Client
EMERGENT BIOSOLUTIONS INC.
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

H.R. 2471 - Consolidated Appropriations Act, 2022 Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines HR 3263 Outreach - DHS Medical Countermeasures Act

LobbyistCovered position, as disclosed
JAMES L ERVIN —
COLBY MILLER —

Contacted: HOUSE OF REPRESENTATIVES; Homeland Security, Dept of (DHS); SENATE

Bills named: H.R. 2366 (117th), H.R. 3263 (117th), H.R. 2379 (117th), S. 987 (117th), S. 1457 (117th), H.R. 5224 (117th), H.R. 2471 (117th), H.R. 4341 (117th), H.R. 6119 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.